復宏漢霖(02696.HK)與國藥控股訂立經銷及採購框架協議
格隆匯4月24日丨復宏漢霖-B(02696.HK)發佈公告,公司管線中部分產品已處於3期臨牀試驗及╱或已向國家藥監局遞交新藥藥證申請(其中包括HLX02(赫賽汀生物類似藥(曲妥珠單抗)),其新藥藥證申請現正由國家藥監局進行優先審評)。同時,作為商業化策略的一部分,集團已識別及建立向終端客户交付產品的經銷商網絡。經考慮(其中包括)國藥控股廣闊的經銷網絡及市場地位,2020年4月24日,除集團或會訂立的任何其他經銷協議之外,公司與國藥控股訂立國控經銷框架協議,據此,公司同意由國藥控股集團作為集團部分生物製藥產品的經銷商之一。於同日,出於經營發展需要,公司與國藥控股亦訂立國控採購框架協議,據此,公司同意自國藥控股集團採購(i)倉儲及物流服務及(ii)原材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.